Kim TY - Search Results

1

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ. Sclafani F, et al. Among authors: kim tw, kim ty, kim sy. J Natl Cancer Inst. 2015 Sep 23;107(12):djv258. doi: 10.1093/jnci/djv258. Print 2015 Dec. J Natl Cancer Inst. 2015. PMID: 26405092 Clinical Trial.

2

A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer.

Kim TY, Yang SH, Lee SH, Park YS, Im YH, Kang WK, Ha SH, Park CI, Heo DS, Bang YJ, Kim NK. Kim TY, et al. Among authors: kim nk. Am J Clin Oncol. 2002 Jun;25(3):238-43. doi: 10.1097/00000421-200206000-00007. Am J Clin Oncol. 2002. PMID: 12040280 Clinical Trial.

3

Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.

Lee JJ, Kim TM, Yu SJ, Kim DW, Joh YH, Oh DY, Kwon JH, Kim TY, Heo DS, Bang YJ, Kim NK. Lee JJ, et al. Among authors: kim dw, kim ty, kim tm, kim nk. Jpn J Clin Oncol. 2004 Jul;34(7):400-4. doi: 10.1093/jjco/hyh068. Jpn J Clin Oncol. 2004. PMID: 15342667 Clinical Trial.

4

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.

Han SW, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT, Kim TY, Heo DS, Bang YJ, Kim NK. Han SW, et al. Among authors: kim dw, kim ty, kim yt, kim nk. Int J Cancer. 2005 Jan 1;113(1):109-15. doi: 10.1002/ijc.20550. Int J Cancer. 2005. PMID: 15386420 Free article. Clinical Trial.

5

Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.

Kim DW, Jo YH, Kim JH, Wu HG, Rhee CS, Lee CH, Kim TY, Heo DS, Bang YJ, Kim NK. Kim DW, et al. Among authors: kim ty, kim nk, kim jh. Cancer. 2004 Nov 15;101(10):2257-60. doi: 10.1002/cncr.20648. Cancer. 2004. PMID: 15484215 Free article.

6

A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma.

Sun JM, Han W, Im SA, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ, Choe KJ, Kim NK. Sun JM, et al. Among authors: kim ty, kim nk. Cancer. 2004 Dec 1;101(11):2516-22. doi: 10.1002/cncr.20665. Cancer. 2004. PMID: 15517588 Free article.

7

Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.

Kim SY, Kim HP, Kim YJ, Oh DY, Im SA, Lee D, Jong HS, Kim TY, Bang YJ. Kim SY, et al. Among authors: kim yj, kim ty, kim hp. Int J Oncol. 2008 Jan;32(1):89-95. Int J Oncol. 2008. PMID: 18097546

8

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.

Kim HP, Han SW, Kim SH, Im SA, Oh DY, Bang YJ, Kim TY. Kim HP, et al. Among authors: kim sh, kim ty. Mol Cancer Ther. 2008 Mar;7(3):607-15. doi: 10.1158/1535-7163.MCT-07-2068. Mol Cancer Ther. 2008. PMID: 18347147

9

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK. Ryu MH, et al. Among authors: kim tw, kim ty, kim mk. Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. Oncology. 2009. PMID: 19307738 Clinical Trial.

10

Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.

Han HS, Kim JS, Park JH, Jeon YK, Lee KW, Oh DY, Kim JH, Park SY, Im SA, Kim TY, Park IA, Bang YJ. Han HS, et al. Among authors: kim ty, kim js, kim jh. J Korean Med Sci. 2009 Oct;24(5):910-7. doi: 10.3346/jkms.2009.24.5.910. Epub 2009 Sep 24. J Korean Med Sci. 2009. PMID: 19794992 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,567 results

Search Page